Cartesian Therapeutics, Inc. — Director's Dealing 2016

Jun 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-27

Reporting Person: TAS Partners, LLC (Director)
Reporting Person: Leukon Investments, LP (Director)
Reporting Person: SPRINGER TIMOTHY A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-27	Common Stock	C	506015	—	Acquired	527028	Indirect
2016-06-27	Common Stock	C	425874	—	Acquired	445576	Indirect
2016-06-27	Common Stock	P	710000	$14.00	Acquired	1237028	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-27	Series B Convertible Preferred Stock	$	C	157864	Disposed		Common Stock (157864)	Indirect
2016-06-27	Series B Convertible Preferred Stock	$	C	157864	Disposed		Common Stock (157864)	Indirect
2016-06-27	Series C Convertible Preferred Stock	$	C	153742	Disposed		Common Stock (153742)	Indirect
2016-06-27	Series C Convertible Preferred Stock	$	C	93954	Disposed		Common Stock (93954)	Indirect
2016-06-27	Series D Convertible Preferred Stock	$	C	63547	Disposed		Common Stock (63547)	Indirect
2016-06-27	Series D Convertible Preferred Stock	$	C	51355	Disposed		Common Stock (51355)	Indirect
2016-06-27	Series E Convertible Preferred Stock	$	C	84421	Disposed		Common Stock (130862)	Indirect
2016-06-27	Series E Convertible Preferred Stock	$	C	79156	Disposed		Common Stock (122701)	Indirect

Footnotes

F1: Held by Leukon Investments LP ("Leukon").

F2: Held by TAS Partners, LLC ("TAS").

F3: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock automatically converted into common stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

F4: The Series E Convertible Preferred Stock is convertible at any time, at the holder's election and has no expiration date. The Series E Convertible Preferred Stock automatically converted into common stock on an approximately 1-for-1.550115 basis upon the closing of the Issuer's initial public offering.

F5: LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.